Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2022)
20 slides from Nova Eye Medical's shareholder meeting presentation, Nov 17, 2022
Slide 1: Addressing the two leading causes of blindness in the developed world
Addressing the two leading causes of blindness in the developed world Nova Eye Medical Limited (ASX:EYE) Managing Director Presentation to Annual General Meeting 17 November 2022 nova-eye.com | 1
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: Glaucoma Market Strong Global Growth Theme
Glaucoma Market Strong Global Growth Theme Glaucoma is the leading cause of irreversible blindness. The aging global population drives prevalence, representing a significant opportunity for our global business. US$667m CAGR 15% Western Glaucoma Surgical Europe Device market size 144.2 and growth rat
Slide 4: iTrack microcatheter for canaloplasty
• Introduced in 2008 • Microcatheter designed for canaloplasty • Strong body of clinical evidence but technically challenging– requires use of forceps, cutting instruments • Used predominantly by glaucoma surgeons nova-eye.com | 4
Slide 5: iTrack Advance launch
5 • Launched in markets outside of USA and China in June 2022. • Combines microcatheter with an easy-to-use handheld injector. • Designed for all ophthalmic surgery and specialists settings.
Slide 6: iTrack Advance expands addressable surgeon market
200 1,2001 existing surgeon estimated glaucoma The new iTrack™ Advance will appeal to cataract customers surgeon market surgeons as well as glaucoma surgeons, expanding the total addressable market by c.10x. In the USA, iTrack™ is regularly used by approximately 200 specialist glaucoma surgeons. The
Slide 7: FY22 Achievements
FY22 ACHIEVEMENTS The 2022 financial year saw us expand the depth of our operations in the Glaucoma Surgical Consumable Device segment, achieving a series of commercial, market access, product development and clinical goals. Achieved production- Acquired seminal Successfully navigated Continued to i
Slide 8: European Market FY22
European Market FY22 Financial Performance: Strong German sales during the period, up 24% on the prior period. Today, Germany accounts for 17% of total global sales. • Positive sales momentum underscored by the launch of iTrack™ Advance. • Comprehensive clinical and surgical training program launche
Slide 9: USA Market FY22
USA Market FY22 Financial Performance: Sales revenue was down 3% on the prior period. This followed a strong rebound during the 6 months to 30 June 2022 in which sales grew 10%, compared with sales in the 6 months to 31 December 2021. Positive turnaround in sales of our legacy iTrack™ microcatheter
Slide 10: FY22 Glaucoma Operating Result
FY22 Glaucoma Operating Result A $'000’s1 US $'000’s¹ Geographic sales composition: FY21 FY22 FY21 FY22 Sales composition using Sales 13,088 13,137 9,684 9,534 US$: USA 67% (pcp 68%), Western Europe 28% (pcp COGS2 (4,473) (5,123) (3,310) (3,703) 24%), China 5% (pcp 7%) Gross Margin 8,615 8,014 6,374
Slide 11: Sales Update to 31 October 2022
Sales Update to 31 October 2022 Four months ended 31 October 2022: 28% increase • Following the commercial launch of in sales (cc) to the new iTrack™ Advance in select US$3.82 million markets in Europe and Canada in June 2022, revenue up 28% (in Note: 18% sales increase constant currency) to US$3.82
Slide 12: 2RT proprietary nanosecond laser therapy for intermediate AMD
• Age-related macular degeneration (AMD) is the leading cause of blindness in industrialized countries in people over the age of 50 years. • While there have been major advances in the treatment of AMD in its late stages 2RT® is a proprietary, world-first (referred to as Wet AMD), there has been lit
Slide 13: Clinical Evidence Supports Plan for Successful Confirmatory Pivotal Study
Clinical Evidence Supports Plan for Successful Confirmatory Pivotal Study 1. Gunawan, JR., et al., Effect of subthreshold nanosecond laser on retinal structure and function in intermediate age-related macular 16. Wood, JPM., et al., Physiological response of the retinal pigmented epithelium to 3-ns
Slide 14: 2RT for Intervention in AMD Progression
2RT® for Intervention in AMD Progression Intervention concept schematic based on a post hoc analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in pee
Slide 15: Initial Recruitment of Investigator Sites, Pivotal Study
Initial Recruitment of Investigator Sites, Pivotal Study Significant milestone in the Company’s plans to conduct the multi-center confirmatory study, intended to validate the results of the 2018 “LEAD” Study: twenty-eight (28) of the world’s leading retinal researchers and clinical experts across Eu
Slide 16: 2RT Development Milestones
2RT® Development Milestones Our current strategy for 2RT® is to undertake a confirmatory pivotal clinical study at sites in Europe, Australia, Canada and ultimately the USA to gain FDA clearance for the treatment of intermediate AMD funded by partners. ✓ PRE-CLINCAL WORK Completed Investigational De
Slide 17: Nova Eye Group Outlook
Nova Eye Group Outlook • Sales of new iTrack™ Advance canaloplasty device in markets in Europe and Canada are expected to continue to grow; however, the total sales growth for the remainder of the 2023 fiscal year will be largely contingent on the timing of marketing clearance of the iTrack™ Advance
Slide 18: Financials and Corporate Snapshot
ASX: EYE Financials and Corporate Snapshot Australian Securities EYE 9% Exchange Ticker Management + Board Exchange Ownership Nova Eye Medical Limited (15 November 2022 fully diluted) 146M A$13.1M A$30.4M Shares on Issue Revenues Net Assets (12 months 30 June 2022) (as at 30 June 2022) A$43.8M A$8.0
Slide 19: Business Snapshot
ASX: EYE Business Snapshot Nova Eye Medical Limited (ASX:EYE) comprises two business units, Glaucoma and AMD/2RT® – these segments address the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Strategy Progre
Slide 20: Nova Eye Medical Limited contacts
Limite Medic Nova Eye al d Tom Spurling Mark Flynn Kate Hunt Managing Director Investor Relations Chief Commercial Officer M: +61 417 818 658 M: +61 416 068 733 M: +61 404 080 679 E: tspurling@nova-eye.com E: mflynn@nova-eye.com E: khunt@nova-eye.com
Nova Eye Medical — Shareholder Meeting (November 2022) on 6ix